Effect of Uncaria tomentosa extract on apoptosis triggered by oxaliplatin exposure on HT29 cells

Evidence-based Complementary and Alternative Medicine

Volumn 2014, Issue , 2014, Pages

  De Oliveira, Liliane Z ^a   Farias, Iria Luiza G ^a   Rigo, Melânia L ^a   Glanzner, Werner G ^a   Gonçalves, Paulo Bayard D ^a   Cadoná, Francine C ^a   Cruz, Ivana B ^a   Farias, Júlia G ^a   Duarte, Marta M M F ^b   Franco, Luzia ^c   Bertol, Gustavo ^c   Colpo, Elisangela ^a   Brites, Patricia C ^a   Rocha, João Batista T ^a   Leal, Daniela B R ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

^b UNIVERSIDADE LUTERANA DO BRASIL   (Brazil)

^c Herbarium Laboratorio Botanico Ltda   (Sri Lanka)

Author keywords

[No Author keywords available]

Indexed keywords

ANNEXIN; CASPASE 3; CASPASE 8; CATALASE; DNA FRAGMENT; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; INTERLEUKIN 1BETA CONVERTING ENZYME; OXALIPLATIN; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; UNCARIA TOMENTOSA EXTRACT;

ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER THERAPY; CELL CULTURE; CLINICAL EVALUATION; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOGENETICS; CYTOTOXICITY; DNA REPAIR; DRUG EFFECT; DRUG EXPOSURE; ENZYME ACTIVITY; GENOTOXICITY; HT 29 CELL LINE; HUMAN; ONION; UNCARIA TOMENTOSA;

EID: 84981512063     PISSN: 1741427X     EISSN: 17414288     Source Type: Journal    
DOI: 10.1155/2014/274786     Document Type: Article

References (48)

1. Block K. I.; Koch A. C.; Mead M. N.; Tothy P. K.; Newman R. A.; Gyllenhaal C.; Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. International Journal of Cancer 2008 123 6 1227 1239 10.1002/ijc.23754 2-s2.0-49749097982
2. Schumacker P. T.; Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell 2006 10 3 175 176 2-s2.0-33748165596 10.1016/j.ccr.2006.08.015
3. Janssen A. M. L.; Bosman C. B.; Sier C. F. M.; Griffioen G.; Kubben F. J. G. M.; Lamers C. B. H. W.; Van Krieken J. H. J. M.; Van de Velde C. J. H.; Verspaget H. W.; Superoxide dismutases in relation to the overall survival of colorectal cancer patients. British Journal of Cancer 1998 78 8 1051 1057 2-s2.0-0031683422 10.1038/bjc.1998.626
4. Hussain S. P.; Amstad P.; He P.; p53-Induced up-regulation of MnSOD and GPx but not Catalase increases oxidative stress and apoptosis. Cancer Research 2004 64 7 2350 2356 2-s2.0-11144356558 10.1158/0008-5472.CAN-2287-2
5. Priego S.; Feddi F.; Ferrer P.; Mena S.; Benlloch M.; Ortega A.; Carretero J.; Obrador E.; Asensi M.; Estrela J. M.; Natural polyphenols facilitate elimination of HT-29 colorectal cancer xenografts by chemoradiotherapy: a Bcl-2- and superoxide dismutase 2-dependent mechanism. Molecular Cancer Therapeutics 2008 7 10 3330 3342 2-s2.0-55749100319 10.1158/1535-7163.MCT-08-0363
6. Heitzman M. E.; Neto C. C.; Winiarz E.; Vaisberg A. J.; Hammond G. B.; Ethnobotany, phytochemistry and pharmacology of Uncaria (Rubiaceae). Phytochemistry 2005 66 1 5 29 10.1016/j.phytochem.2004.10.022 2-s2.0-11844297322
7. Keplinger K.; Laus G.; Wurm M.; Dierich M. P.; Teppner H.; Uncaria tomentosa (Willd.) DC.-ethnomedicinal use and new pharmacological, toxicological and botanical results. Journal of Ethnopharmacology 1998 64 1 23 34 10.1016/S0378-8741(98)00096-8 2-s2.0-0031987248
8. United States Pharmacopeial Convention, United States Pharmacopeia (USP 36) 2013 36th Rockville, Md, USA United States Pharmacopeial Convention
9. Pilarski R.; Zieliński H.; Ciesiołka D.; Gulewicz K.; Antioxidant activity of ethanolic and aqueous extracts of Uncaria tomentosa (Willd.) DC. Journal of Ethnopharmacology 2006 104 1-2 18 23 10.1016/j.jep.2005.08.046 2-s2.0-32644441184
10. Farias I.; do Carmo Araújo M.; Zimmermann E. S.; Uncaria tomentosa stimulates the proliferation of myeloid progenitor cells. Journal of Ethnopharmacology 2011 137 1 856 863 10.1016/j.jep.2011.07.011 2-s2.0-80052034805
11. Eberlin S.; dos Santos L. M. B.; Queiroz M. L. S.; Uncaria tomentosa extract increases the number of myeloid progenitor cells in the bone marrow of mice infected with Listeria monocytogenes. International Immunopharmacology 2005 5 7-8 1235 1246 10.1016/j.intimp.2005.03.001 2-s2.0-19444372526
12. Pilarski R.; Filip B.; Wietrzyk J.; Kuras̈ M.; Gulewicz K.; Anticancer activity of the Uncaria tomentosa (Willd.) DC. preparations with different oxindole alkaloid composition. Phytomedicine 2010 17 14 1133 1139 10.1016/j.phymed.2010.04.013 2-s2.0-78149412523
13. Cheng A.-C.; Jian C.-B.; Huang Y.-T.; Lai C.-S.; Hsu P.-C.; Pan M.-H.; Induction of apoptosis by Uncaria tomentosa through reactive oxygen species production, cytochrome c release, and caspases activation in human leukemia cells. Food and Chemical Toxicology 2007 45 11 2206 2218 10.1016/j.fct.2007.05.016 2-s2.0-34548820421
14. de Martino L.; Martinot J. L. S.; Franceschelli S.; Leone A.; Pizza C.; de Feo V.; Proapoptotic effect of Uncaria tomentosa extracts. Journal of Ethnopharmacology 2006 107 1 91 94 2-s2.0-33745934133 10.1016/j.jep.2006.02.013
15. Bacher N.; Tiefenthaler M.; Sturm S.; Stuppner H.; Ausserlechner M. J.; Kofler R.; Konwalinka G.; Oxindole alkaloids from Uncaria tomentosa induce apoptosis in proliferating, G0/G1-arrested and bcl-2-expressing acute lymphoblastic leukaemia cells. British Journal of Haematology 2006 132 5 615 622 10.1111/j.1365-2141.2005.05907.x 2-s2.0-33644883914
16. Dreifuss A. A.; Bastos-Pereira A. L.; Fabossi I. A.; Uncaria tomentosa exerts extensive anti-neoplastic effects against the walker-256 tumour by modulating oxidative stress and not by alkaloid activity. PLoS ONE 2013 8 2 e54618 10.1371/journal.pone.0054618 2-s2.0-84873600656
17. Bertol G.; Franco L.; de Oliveira B. H.; HPLC analysis of oxindole alkaloids in Uncaria tomentosa: sample preparation and analysis optimisation by factorial design. Phytochemical Analysis 2012 23 2 143 151 10.1002/pca.1335 2-s2.0-84857231546
18. Singh N. P.; McCoy M. T.; Tice R. R.; Schneider E. L.; A simple technique for quantitation of low levels of DNA damage in individual cells. Experimental Cell Research 1988 175 1 184 191 10.1016/0014-4827(88)90265-0 2-s2.0-0023919963
19. Tice R. R.; Agurell D.; Anderson D.; Burlinson B.; Hartmann A.; Kobayashi H.; Miyamae Y.; Rojas E.; Ryu J. C.; Sasaki Y. F.; Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environmental and Molecular Mutagenesis 2000 35 3 206 221
20. Bradford M. M.; A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Analytical Biochemistry 1976 72 1-2 248 254 10.1016/0003-2697(76)90527-3 2-s2.0-0017184389
21. 2 solutions in the UV). Analytical Biochemistry 1972 49 2 474 478 10.1016/0003-2697(72)90451-4 2-s2.0-0015416039
22. McCord J. M.; Fridovich I.; Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). The Journal of Biological Chemistry 1969 244 22 6049 6055 2-s2.0-0014691242
23. Ali S. F.; Le Bel C. P.; Bondy S. C.; Reactive oxygen species formation as a biomarker of methylmercury and trimethyltin neurotoxicity. Neurotoxicology 1992 13 3 637 648 2-s2.0-0026483404
24. Wurm M.; Kacani L.; Laus G.; Keplinger K.; Dierich M. P.; Pentacyclic oxindole alkaloids from Uncaria tomentosa induce human endothelial cells to release a lymphocyte-proliferation-regulating factor. Planta Medica 1998 64 8 701 704 10.1055/s-2006-957561 2-s2.0-0032406658
25. Deng G. E.; Frenkel M.; Cohen L.; Evidence-based clinical practice guidelines for integrative oncology: complementary therapies and botanicals. Journal of the Society for Integrative Oncology 2009 7 3 85 120 10.2310/7200.2009.0019 2-s2.0-73349124147
26. Foster B. C.; Vandenhoek S.; Hana J.; Krantis A.; Akhtar M. H.; Bryan M.; Budzinski J. W.; Ramputh A.; Arnason J. T.; In vitro inhibition of human cytochrome P450-mediated metabolism of marker substrates by natural products. Phytomedicine 2003 10 4 334 342 10.1078/094471103322004839 2-s2.0-0037911509
27. FDA,. 2006, http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm
28. Lentz F.; Tran A.; Rey E.; Pons G.; Tréluyer J.-M.; Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications. American Journal of PharmacoGenomics 2005 5 1 21 33 2-s2.0-20444370320 10.2165/00129785-200505010-00002
29. Santos Araújo M. D. C.; Farias I. L.; Gutierres J.; Dalmora S. L.; Flores N.; Farias J.; Cruz I. D.; Chiesa J.; Morsch V. M.; Chitolina Schetinger M. R.; Uncaria tomentosa-adjuvant treatment for breast cancer: clinical trial. Evidence-Based Complementary and Alternative Medicine 2012 2012 8 676984 10.1155/2012/676984 2-s2.0-84864914124
30. Reyes-Zurita F. J.; Pachón-Peña G.; Lizárraga D.; Rufino-Palomares E. E.; Cascante M.; Lupiáñez J. A.; The natural triterpene maslinic acid induces apoptosis in HT29 colon cancer cells by a JNK-p53-dependent mechanism. BMC Cancer 2011 11, article 154 10.1186/1471-2407-11-154 2-s2.0-79955139265
31. Kurokawa M.; Kornbluth S.; Caspases and kinases in a death grip. Cell 2009 138 5 838 854 2-s2.0-69449095860 10.1016/j.cell.2009.08.021
32. Berindan-Neagoe I.; Braicu C.; Pileczki V.; Petric R. C.; Miron N.; Balacescu O.; Iancu D.; Ciuleanu T.; 5-fluorouracil potentiates the anti-cancer effect of oxaliplatin on Colo320 colorectal adenocarcinoma cells. Journal of Gastrointestinal and Liver Diseases 2013 22 1 37 43 2-s2.0-84875460992
33. Yang X.; Chang H. Y.; Baltimore D.; Autoproteolytic activation of pro-caspases by oligomerization. Molecular Cell 1998 1 2 319 325 10.1016/S1097-2765(00)80032-5 2-s2.0-0031615875
34. Lee S. Y.; Debnath T.; Kim S.-K.; Lim B. O.; Anti-cancer effect and apoptosis induction of cordycepin through DR3 pathway in the human colonic cancer cell HT-29. Food and Chemical Toxicology 2013 60 439 447 10.1016/j.fct.2013.07.068 2-s2.0-84883226491
35. von Reyher U.; Sträter J.; Kittstein W.; Gschwendt M.; Krammer P. H.; Möller P.; Colon carcinoma cells use different mechanisms to escape CD95-mediated apoptosis. Cancer Research 1998 58 3 526 534 2-s2.0-2642634799
36. O'Connell J.; Bennett M. W.; Nally K.; Houston A.; O'Sullivan G. C.; Shanahan F.; Altered mechanisms of apoptosis in colon cancer: Fas resistance and counterattack in the tumor-immune conflict. Annals of the New York Academy of Sciences 2000 910 178 195 2-s2.0-0033913693
37. Gonçalves A.; Braguer D.; Carles G.; André N.; Prevôt C.; Briand C.; Caspase-8 activation independent of CD95/CD95-L interaction during paclitaxel-induced apoptosis in human colon cancer cells (HT29-D4). Biochemical Pharmacology 2000 60 11 1579 1584 10.1016/S0006-2952(00)00481-0 2-s2.0-0034575597
38. Lacour S.; Hammann A.; Grazide S.; Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells. Cancer Research 2004 64 10 3593 3598 10.1158/0008-5472.CAN-03-2787 2-s2.0-2442693091
39. Laurent A.; Nicco C.; Chéreau C.; Goulvestre C.; Alexandre J.; Alves A.; Lévy E.; Goldwasser F.; Panis Y.; Soubrane O.; Weill B.; Batteux F.; Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Research 2005 65 3 948 956 2-s2.0-20844447150
40. Alexandre J.; Hu Y.; Lu W.; Pelicano H.; Huang P.; Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species. Cancer Research 2007 67 8 3512 3517 10.1158/0008-5472.CAN-06-3914 2-s2.0-34248582844
41. Priego S.; Feddi F.; Ferrer P.; Mena S.; Benlloch M.; Ortega A.; Carretero J.; Obrador E.; Asensi M.; Estrela J. M.; Natural polyphenols facilitate elimination of HT-29 colorectal cancer xenografts by chemoradiotherapy: a Bcl-2- and superoxide dismutase 2-dependent mechanism. Molecular Cancer Therapeutics 2008 7 10 3330 3342 10.1158/1535-7163.MCT-08-0363 2-s2.0-55749100319
42. Karlsson M.; Kurz T.; Brunk U. T.; Nilsson S. E.; Frennesson C. I.; What does the commonly used DCF test for oxidative stress really show? Biochemical Journal 2010 428 2 183 190 10.1042/BJ20100208 2-s2.0-77952573307
43. Lentz F.; Tran A.; Rey E.; Pons G.; Tréluyer J.-M.; Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications. American Journal of PharmacoGenomics 2005 5 1 21 33 10.2165/00129785-200505010-00002 2-s2.0-20444370320
44. Arnould S.; Hennebelle I.; Canal P.; Bugat R.; Guichard S.; Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. European Journal of Cancer 2003 39 1 112 119 10.1016/S0959-8049(02)00411-2 2-s2.0-0037213983
45. Seetharam R. N.; Sood A.; Basu-Mallick A.; Augenlicht L. H.; Mariadason J. M.; Goel S.; Oxaliplatin resistance induced by ERCC1 up-regulation is abrogated by siRNA-mediated gene silencing in human colorectal cancer cells. Anticancer Research 2010 30 7 2531 2538 2-s2.0-77955792964
46. Mallick A. B.; Seetharam R.; Sood A.; Mariadason J.; Goel S.; Evaluation of inducible expression of ERCC1 as a biomarker of drug response in human colorectal cancer cell lines. International Journal of Clinical Oncology 2010 28 supplement 15 14048
47. Tsai M.-S.; Weng S.-H.; Kuo Y.-H.; Chiu Y.-F.; Lin Y.-W.; Synergistic effect of curcumin and cisplatin via down-regulation of thymidine phosphorylase and excision repair cross-complementary 1 (ERCC1). Molecular Pharmacology 2011 80 1 136 146 10.1124/mol.111.071316 2-s2.0-79959321665
48. Ko J.-C.; Su Y.-J.; Lin S.-T.; Jhan J.-Y.; Ciou S.-C.; Cheng C.-M.; Chiu Y.-F.; Kuo Y.-H.; Tsai M.-S.; Lin Y.-W.; Emodin enhances cisplatin-induced cytotoxicity via down-regulation of ERCC1 and inactivation of ERK1/2. Lung Cancer 2010 69 2 155 164 10.1016/j.lungcan.2009.10.013 2-s2.0-77954143718.